Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Liabilities and Shareholders Equity (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Liabilities and Shareholders Equity for 13 consecutive years, with $1.3 billion as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 20.85% to $1.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.6 billion through Dec 2025, up 7.83% year-over-year, with the annual reading at $1.3 billion for FY2025, 20.85% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $1.3 billion at Madrigal Pharmaceuticals, down from $1.4 billion in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $1.4 billion in Q3 2025, with the low at $158.6 million in Q3 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $631.1 million, with a median of $347.5 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity tumbled 47.93% in 2022, then surged 351.02% in 2024.
  • Over 5 years, Liabilities and Shareholders Equity stood at $273.3 million in 2021, then skyrocketed by 32.65% to $362.6 million in 2022, then skyrocketed by 76.67% to $640.5 million in 2023, then skyrocketed by 62.71% to $1.0 billion in 2024, then increased by 20.85% to $1.3 billion in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $1.3 billion, $1.4 billion, and $1.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.